Table 2.

A summary of reported fifteen cases of rhabdomyolysis associated with fenofibrate therapy.

	References	Year	Age	Sex	Medical History	Other drug	Fenofibrate	BUN	Cr	CK
1	Wu et al. [6]	2009	52	F	DL		200 mg, for 1 mo	43.8
2	De Souza et al. [7]	2009	54	M	CRF, DL, HT, Hypothyroidism		200 mg, for 2 mo	120	4.9	52749
3	Çetinkaya et al. [5]	2008	60	F	DM-II, HT, DL		200 mg, for NA		4.2	11867
4	Unal et al. [1]	2008	56	F	CAD, DL	Pravastatin	200 mg, for 2 mo	37	2.6	97392
			58	M	CABG, DL	Atorvastatin	200 mg, for 1 mo	36	3.6	96639
5	Yildiz et al. [8]	2008	74	M	CABG, HT, DL		267 mg, for 2 wk	224	5.3	26680
6	Tahmaz et al. [9]	2007	42	F	HT, DL		250 mg, for 4 wk	90	5.5	21000
7	Dedhia and Munsi [10]	2007	68	M	CABGx2, HT, DL	Rosuvastatin	160 mg, for 3 wk		2.3	23665
8	Jacob et al. [11]	2005	70	M	DM-II, HT, DL, Hypothyroidism	Simvastatin	160 mg, for 4 wk		2.7	10936
9	Ireland et al. [12]	2005	67	F	HT, DL	Rosuvastatin	160 mg, for 2 wk	58	3.6	13808
10	Kursat et al. [13]	2005	63	F	HT, DL, Hypothyroidism	Simvastatin	200 mg, for 4 wk	188	4.5	8842
11	Ghosh et al. [14]	2004	58	M	CAD, DL		200 mg, for 5 wk			1129
12	Barker et al. [15]	2003	56	F	HT, DM-II, DL		200 mg, for 10 d		2	5632
13	Clouatre et al. [16]	1999	57	F	CRF, DL, HT, Hypothyroidism		200 mg, for 4 wk			8850
			55	F	CRF, PCRD, DL, Hypothyroidism	Simvastatin	200 mg, for 3 wk			11360

BUN: blood urea nitrogen (mg/dl), Cr: creatinine (mg/dl), DM: diabetes mellitus, CRF: chronic renal failure, CK: serum creatine kinase (IU/L), HT: hypertension, DL: dyslipidemia, CAD: coronary artery disease, CABG: coronary artery by-pass graft, and PCRD: polycystic renal disease.